A detailed history of Parallel Advisors, LLC transactions in Cara Therapeutics, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 4 shares of CARA stock, worth $1. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4
Previous 4 -0.0%
Holding current value
$1
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

May 20, 2024

SELL
$1.67 - $3.33 $141 - $283
-85 Reduced 95.51%
4 $0
Q3 2023

Nov 13, 2023

SELL
$1.67 - $3.33 $141 - $283
-85 Reduced 95.51%
4 $0
Q2 2023

May 20, 2024

BUY
$2.83 - $4.94 $240 - $419
85 Added 2125.0%
89 $0
Q2 2023

Aug 04, 2023

BUY
$2.83 - $4.94 $240 - $419
85 Added 2125.0%
89 $0
Q4 2021

Jan 20, 2022

SELL
$11.99 - $18.14 $527 - $798
-44 Reduced 91.67%
4 $0
Q2 2020

Jul 16, 2020

BUY
$12.39 - $17.33 $545 - $762
44 Added 1100.0%
48 $0
Q2 2018

Jul 30, 2018

BUY
$11.6 - $19.27 $46 - $77
4 New
4 $0

Others Institutions Holding CARA

About Cara Therapeutics, Inc.


  • Ticker CARA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,725,900
  • Market Cap $14.5M
  • Description
  • Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...
More about CARA
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.